Tasquinimod clinical trials
Also written ABR-215050.
How each study uses tasquinimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tasquinimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 5
Ipsen (3) · Active Biotech AB (3) · Andrew J. Armstrong, MD (1) · M.D. Anderson Cancer Center (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · University of Pennsylvania (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Studies
Open first, then newest update. How each study uses tasquinimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06327100Written as TasquinimodHow we know
- Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 InhibitionRecruitingPhase 1/2Stichting Hemato-Oncologie voor Volwassenen NederlandNCT06605586Written as TasquinimodHow we know
- Tasquinimod for the Treatment of Relapsed or Refractory MyelomaTerminatedPhase 1University of PennsylvaniaNCT04405167Written as TasquinimodHow we know
- Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate CancerTerminatedPhase 3IpsenNCT02057666Written as TasquinimodHow we know
- A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based ChemotherapyTerminatedPhase 2IpsenNCT01732549Written as TasquinimodHow we know
- A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric CancersCompletedPhase 2IpsenNCT01743469Written as TasquinimodHow we know
- The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate CancerCompletedPhase 1Andrew J. Armstrong, MDNCT01513733Written as tasquinimodHow we know
- A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate CancerWithdrawnPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02396368Written as TasquinimodHow we know
- Efficacy Study of ABR-215050 to Treat Prostate CancerCompletedPhase 2Active Biotech ABNCT00560482Written as ABR-215050, tasquinimodHow we know
- A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate CancerCompletedPhase 3Active Biotech ABNCT01234311Written as tasquinimodHow we know
- A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy SubjectsCompletedPhase 1Active Biotech ABNCT01048203Written as ABR-215050How we know
Given beside what is tested · 1 — tasquinimod is usual care or a partner of the new treatment
Codes
What other systems call tasquinimod · ClinicalTrials.gg INT005019
- MeSH (NLM) C516109tasquinimodConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 756U07KN1RTASQUINIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q7687612tasquinimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74080TasquinimodOne source FDA
- DrugBank DB05861One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C516109 | tasquinimod | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 756U07KN1R | TASQUINIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7687612 | tasquinimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74080 | Tasquinimod | One source FDA |
| DrugBank | DB05861 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.